Licensing opportunities
Cardiovascular
Our licensing opportunities tagged with Cardiovascular are shown below.
-
Method and apparatus for assessing cardiovascular fitness
A novel method and apparatus for monitoring the performance of a person undertaking exercise to assess their cardiovascular fitness, in particular, by calculating VO2 max, the maximal oxygen uptake per unit time.
-
Generation of origin-specific vascular smooth muscle cells
Origin-specific vascular smooth muscle cells have been generated from embryonic stem cells including iPS cells using chemically defined culture conditions. The derived cells have been extensively characterized including functional characterization. Broad applications in vascular regenerative medicine.
-
Novel Series of 5-HT1B Antagonists for Pulmonary Arterial Hypertension
A novel drug-like series of 5-HT1B antagonists with excellent potential for treatment of pulmonary arterial hypertension (PAH) with a low side effect profile and in-vivo data showing reversal of PAH.
-
Novel Apoptosis Imaging Agents
A novel agent for use in molecular imaging of apoptotic cells that can be cross-linked to a variety of contrast agents and is highly suitable for use with imaging technologies such as MRI, PET and SPECT. This imaging agent may be useful as a prognostic indicator of treatment outcome for cancer or cardiac plaque formation.
-
Novel Murine Model of Advanced Vulnerable Atherosclerosis
Transgenic mice are engineered so that on induction they rapidly and predictably develop a disease state that shares major features of advanced vulnerable atherosclerosis in humans. This valuable model is highly suited to studies of cardiovascular drugs which stabilise atherosclerotic plaques and the long term study of arterial diseases such as aneurysm formation, angioplasty restenosis and atherosclerosis.